BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24644061)

  • 1. WNT/β-catenin signaling and hepatocellular carcinoma.
    Wands JR; Kim M
    Hepatology; 2014 Aug; 60(2):452-4. PubMed ID: 24644061
    [No Abstract]   [Full Text] [Related]  

  • 2. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
    Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
    Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W; Kim H; Ho M
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3.
    Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW
    J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment.
    Ma H; Chen S; He Y; Huang J; Xu Y; Wang C; Lei C; Lu T; Xiao S; Mao J; Xu Y; Guo H; Li B; Zhang M; He X
    Protein Cell; 2018 Jul; 9(7):664-669. PubMed ID: 29143211
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
    Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of Wnt/β-catenin signaling pathway in promoting tumorigenesis of hepatocellular carcinoma].
    Xie L; Jiang H; Wu F
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jun; 34(6):913-7. PubMed ID: 24968856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation.
    Jiang N; Chen WJ; Zhang JW; Xu C; Zeng XC; Zhang T; Li Y; Wang GY
    Oncotarget; 2015 Apr; 6(10):7866-79. PubMed ID: 25797263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal radioimmunoassays and HBV-DNA hybridisation in hepatocellular carcinoma.
    Wands JR; Isselbacher KJ; Brechot C; Tiollais P
    Lancet; 1985 Feb; 1(8426):455. PubMed ID: 2857827
    [No Abstract]   [Full Text] [Related]  

  • 10. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma.
    Dahmani R; Just PA; Perret C
    Clin Res Hepatol Gastroenterol; 2011 Nov; 35(11):709-13. PubMed ID: 21778132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma.
    Scott FR; el-Refaie A; More L; Scheuer PJ; Dhillon AP
    Histopathology; 1996 May; 28(5):472-4. PubMed ID: 8735726
    [No Abstract]   [Full Text] [Related]  

  • 12. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
    Nakano K; Ishiguro T; Konishi H; Tanaka M; Sugimoto M; Sugo I; Igawa T; Tsunoda H; Kinoshita Y; Habu K; Orita T; Tsuchiya M; Hattori K; Yamada-Okabe H
    Anticancer Drugs; 2010 Nov; 21(10):907-16. PubMed ID: 20847643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical regulators of Wnt/β-catenin signaling as potential therapeutic targets in Hepatocellular Carcinoma.
    Chen J; Rajasekaran M; Hui KM
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1142-1149. PubMed ID: 28429652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Two mouse hybridomas secreting monoclonal antibodies against human liver carcinoma and their antibody specificity].
    Xie H; Yang ZH; Chen RM; Yao Z; Wang BM; Guo SY; Yan ZF
    Shi Yan Sheng Wu Xue Bao; 1985 Jun; 18(2):263-70. PubMed ID: 2424200
    [No Abstract]   [Full Text] [Related]  

  • 15. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
    Fleming BD; Ho M
    Toxins (Basel); 2016 Sep; 8(10):. PubMed ID: 27669301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunolocation of metastases from adenocarcinoma of the colon: using a hepatoma antibody.
    Divgi CR; Cohen AM
    Hepatology; 1990 May; 11(5):891-2. PubMed ID: 2161398
    [No Abstract]   [Full Text] [Related]  

  • 17. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
    Wang R; Sun Q; Wang P; Liu M; Xiong S; Luo J; Huang H; Du Q; Geller DA; Cheng B
    Oncotarget; 2016 Feb; 7(5):5754-68. PubMed ID: 26735577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
    Capurro M; Martin T; Shi W; Filmus J
    J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    Wang W; Pan Q; Fuhler GM; Smits R; Peppelenbosch MP
    J Gastroenterol; 2017 Apr; 52(4):419-431. PubMed ID: 28035485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
    Peng YY; He YH; Chen C; Xu T; Li L; Ni MM; Meng XM; Huang C; Li J
    Cancer Lett; 2016 Jun; 376(1):10-21. PubMed ID: 26975630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.